newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

  • Chemomab Therapeutics and Scipher Medicine are advancing a proposed merger with a closing expected in the first quarter of 2027.
  • The SEC declared the Form S-4 registration statement effective on October 30, 2026, following a proxy statement supplement on November 10, 2026.
  • A special meeting for Chemomab shareholders to vote on the merger is scheduled for December 4, 2026, at 3:00 pm Israel time.
  • Chemomab and Scipher completed a Type B Pre-IND interaction with the FDA regarding a Phase 2 trial of nebokitug for rheumatoid arthritis, receiving feedback consistent with their development plans.
  • The combined company plans to initiate the Phase 2 nebokitug trial in the first half of 2027, with topline results projected for the first half of 2028.
  • Post-merger, the combined entity will operate as Scipher Medicine Corporation, trading on Nasdaq under the ticker "SCIP," with Dr. Reginald Seeto serving as CEO and Dr. Adi Mor joining the Board.
  • Pre-merger Chemomab shareholders are expected to own approximately 32% of the combined company, while Scipher convertible note holders are expected to own 68%.
  • Pre-merger Chemomab shareholders will receive contingent value rights (CVRs) offering potential payments of $10 million upon FDA approval of nebokitug and $40 million upon Phase 3 initiation or disposition of nebokitug for primary sclerosing cholangitis.
  • A concurrent $30 million private placement financing is planned, led by Northpond Ventures with participation from Khosla Ventures and Blue Owl Healthcare Opportunities, including 100% warrant coverage.
  • Chemomab reported cash, cash equivalents, and short-term bank deposits of $4.7 million as of September 30, 2026.
  • Research and development expenses were $3.7 million for the third quarter of 2026, an increase driven by the recognition of previously prepaid manufacturing costs.
  • General and administrative expenses were $1.4 million for the third quarter of 2026, primarily attributed to costs associated with the proposed merger.
  • The company reported a net loss of $5.1 million for the third quarter of 2026, compared to $1.7 million in the same period of 2025.
  • On November 3, 2026, Chemomab sold 932,203 ADSs to Scipher for approximately $1.1 million to fund operations through the first quarter of 2027.
Company
Chemomab Therapeutics Ltd.
Keywords
Nasdaq:CMMB, Chemomab Therapeutics Ltd., Chemomab, Corporate update, Financial Results, nebokitug, rheumatoid arthritis